Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently
- Sci Rep. 2020 Feb 6;10(1):2024. doi: 10.1038/s41598-020-58718-9.
- 1. Department of Dermatology and Venerology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- 2. CNRS UMR5305 LBTI and University Lyon1, Lyon, France.
- 3. Institute for Medical Biometry and Epidemiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- 4. Pierre Fabre Dermocosmétique, Pierre Fabre Research and Development Center Toulouse, Toulouse, France.
- 5. Microscopy Services Dähnhardt GmbH, Flintbek, Germany.
- 6. Department of Dermatology, Venerology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- 7. Department of Dermatology and Venerology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. [email protected].
The transmembrane protein claudin-1 is a major component of epidermal tight junctions (TJs), which create a dynamic paracellular barrier in the epidermis. Claudin-1 downregulation has been linked to atopic dermatitis (AD) pathogenesis but variable levels of claudin-1 have also been observed in healthy skin. To elucidate the impact of different levels of claudin-1 in healthy and diseased skin we determined claudin-1 levels in AD patients and controls and correlated them to TJ and skin barrier function. We observed a strikingly broad range of claudin-1 levels with stable TJ and overall skin barrier function in healthy and non-lesional skin. However, a significant decrease in TJ barrier function was detected in lesional AD skin where claudin-1 levels were further reduced. Investigations on reconstructed human epidermis expressing different levels of claudin-1 revealed that claudin-1 levels correlated with inside-out and outside-in barrier function, with a higher coherence for smaller molecular tracers. Claudin-1 decrease induced keratinocyte-autonomous IL-1β expression and fostered inflammatory epidermal responses to non-pathogenic Staphylococci. In conclusion, claudin-1 decrease beyond a threshold level results in TJ and epidermal barrier function impairment and induces inflammation in human epidermis. Increasing claudin-1 levels might improve barrier function and decrease inflammation and therefore be a target for AD treatment.